CUPERTINO, Calif., Oct. 28 /PRNewswire-FirstCall/ -- DURECT Corporation (Nasdaq: DRRX) announced today that management is scheduled to present at the following upcoming healthcare conferences in New York, NY.
-- Oppenheimer 19th Annual Healthcare Conference on Tuesday, November 4th at 3:20 p.m. Eastern Time.
-- Barclays Capital Small & Mid-Cap Healthcare Forum on Thursday, November 6th at 2:30 p.m. Eastern Time.
-- Rodman & Renshaw Annual Global Healthcare Conference on Tuesday, November 11th 5:20 p.m. EST.
A live audio webcast of the presentations will be available by accessing DURECT's homepage at http://www.durect.com and clicking "Investor Relations." If you are unable to participate during the live webcast, the call will be archived on DURECT's website under Audio Archive in the "Investor Relations" section.
About DURECT Corporation
DURECT is an emerging specialty pharmaceutical company developing innovative drugs for pain and other chronic diseases, with late-stage development programs including REMOXY(R), POSIDUR(TM), ELADUR(TM) and TRANSDUR(TM)-Sufentanil. DURECT's proprietary oral, transdermal and injectable depot delivery technologies enable new indications and superior clinical/commercial attributes such as abuse deterrence, improved convenience, compliance, efficacy and safety for small molecule and biologic drugs. For more information, please visit http://www.durect.com.
NOTE: POSIDUR(TM), SABER(TM), ORADUR(R), TRANSDUR(TM) and ELADUR(TM) are trademarks of DURECT Corporation. Other referenced trademarks belong to their respective owners. REMOXY, POSIDUR, ELADUR and TRANSDUR-Sufentanil are drug candidates under development and have not been approved for commercialization by the US Food and Drug Administration or other health authorities.
|SOURCE DURECT Corporation|
Copyright©2008 PR Newswire.
All rights reserved